Nitric Oxide

Nitric Oxide

SCHEMBL4247178

O.[N]=O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GUCY1A1GUCY1A2GUCY1B1GUCY1B2

The experimentally established mechanism targets of Nitric Oxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitric Oxide SCHEMBL7560 0.87
Nitric Oxide SCHEMBL3993955 0.87
Nitric Oxide SCHEMBL7184108 0.75
Nitric Oxide SCHEMBL5104249 0.75
Nitric Oxide SCHEMBL6890944 0.75
Nitric Oxide SCHEMBL306589 0.75
Nitric Oxide SCHEMBL2888647 0.75
Nitric Oxide SCHEMBL2890900 0.75
Nitric Oxide SCHEMBL3636459 0.75
Nitric Oxide SCHEMBL2731176 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415810-B2 2'-isopropyl-spiro (3,3'-pyrrolidine oxindole) liver X receptor regulator, preparation method therefor, and use thereof SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2025-09-16 US claimed
EP-4578855-A1 PROLYL HYDROXYLASE INHIBITOR AND USE THEREOF Suzhong Pharmaceutical Group Co., Ltd. (CN) 2025-07-02 EP claimed
EP-4570918-A1 DUAL-LUCIFERASE REPORTER GENE DETECTION SYSTEM AND USE THEREOF BGI Shenzhen (CN) 2025-06-18 EP claimed
US-20250179559-A1 DUAL-LUCIFERASE REPORTER GENE DETECTION SYSTEM, FLUORESCENCE DETECTION KIT, AND METHOD FOR DETECTING LUMINESCENT SIGNAL OF LUCIFERASE BGI SHENZHEN (CN) 2025-06-05 US claimed
WO-2025108404-A1 HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND USE THEREOF 广东东阳光药业股份有限公司 2025-05-30 WO claimed
WO-2025108406-A1 HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR, AND USE THEREOF 广东东阳光药业股份有限公司 2025-05-30 WO claimed
CN-120025326-A Heterocyclic compound of bifunctional chimera for targeting and degrading androgen receptor and application thereof 广东东阳光药业股份有限公司 2025-05-23 CN claimed
CN-120020129-A Substituted nitrogen-containing bicyclic compounds and uses thereof 广东东阳光药业股份有限公司 2025-05-20 CN claimed
EP-4541794-A1 PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUNDS, AND PREPARATION AND USE THEREOF Suzhong Pharmaceutical Group Co., Ltd. (CN) 2025-04-23 EP claimed
US-12252459-B2 Hydrazone amide derivatives and use thereof in preparation of anti-osteoporosis drugs SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2025-03-18 US claimed
US-20220135579-A1 2'-ISOPROPYL-SPIRO (3,3'-PYRROLIDINE OXINDOLE) LIVER X RECEPTOR REGULATOR, PREPARATION METHOD THEREFOR, AND USE THEREOF SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2022-05-05 US claimed
EP-3992195-A1 SPIRO (3,3'-ISOPROPYL PYRROLIDINE OXINDOLE) LIVER X RECEPTOR REGULATOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) 2022-05-04 EP claimed
EP-3992184-A1 HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) 2022-05-04 EP claimed
CN-114392262-A Betulinic acid derivatives for inhibiting nervous system degenerative diseases 河南省生殖健康科学技术研究院(河南省出生缺陷干预工程技术研究中心) 2022-04-26 CN claimed
CN-114344313-A Betulinic acid derivatives for preventing or treating degenerative diseases of nervous system 河南省科学院高新技术研究中心 2022-04-15 CN claimed
CN-114315952-A Tanshinone I derivative, preparation method and application thereof 浙江大学 2022-04-12 CN claimed
WO-2022067566-A1 PYRIMIDINEDIONE COMPOUND CONTAINING SATURATED OXYGEN-CONTAINING HETEROCYCLIC GROUP AND USE THEREOF 广东东阳光药业有限公司 2022-04-07 WO claimed
WO-2022067573-A1 SULFONAMIDE-SUBSTITUTED HETEROARYL PYRIMIDINEDIONE COMPOUND AND USE THEREOF 广东东阳光药业有限公司 2022-04-07 WO claimed
WO-2022037560-A1 PYRIMIDONE DERIVATIVE AND APPLICATION THEREOF IN DRUG 广东东阳光药业有限公司 2022-02-24 WO claimed
WO-2009043108-A1 REMOVAL OF POLLUTANTS FROM A GAS FLOW INDIGO TECHNOLOGIES GROUP PTY LTD (AU) 2009-04-09 WO claimed